Acelyrin reports Q3 EPS (49c), consensus (80c)

Cash, cash equivalents and short-term marketable securities totaled $562.4M at September 30 .The Company expects these to fund operations to mid-2027.”We are executing on our refocused pipeline strategy and are excited by the near-term catalysts ahead for ACELYRIN (SLRN), particularly as we advance subcutaneous lonigutamab into Phase 3 development as the next generation IGF-1R inhibitor for thyroid eye disease. We recently concluded a positive end of phase 2 interaction with the FDA, established a world-class scientific and patient advisory board, and remain on track to initiate our Phase 3 development program in TED next quarter,” said Mina Kim, Chief Executive Officer of ACELYRIN. “We are also looking forward to announcing topline results from our Phase 2b/3 trial of izokibep in uveitis in December 2024 and hosting a lonigutamab investor event in early 2025.”